8,300 Shares in Prestige Consumer Healthcare Inc. $PBH Purchased by Versor Investments LP

Key Points

• Versor Investments LP has acquired 8,300 shares of Prestige Consumer Healthcare Inc. (NYSE: PBH), valued at approximately $714,000, during the first quarter, indicating growing interest from institutional investors.
• Prestige Consumer Healthcare reported earnings per share (EPS) of $0.95 for the last quarter, missing the consensus estimate by $0.06, while revenue declined 6.6% year-over-year, totaling $249.53 million.
• The company's current consensus rating is "Hold", with analysts lowering their target price to $100.00, reflecting cautious sentiment towards its future performance.

Versor Investments LP purchased a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 8,300 shares of the company's stock, valued at approximately $714,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. lifted its stake in Prestige Consumer Healthcare by 4.2% in the first quarter. Raymond James Financial Inc. now owns 568,178 shares of the company's stock valued at $48,846,000 after acquiring an additional 22,738 shares during the last quarter. Alliance Wealth Advisors LLC UT lifted its stake in Prestige Consumer Healthcare by 2.2% in the first quarter. Alliance Wealth Advisors LLC UT now owns 11,783 shares of the company's stock valued at $1,013,000 after acquiring an additional 254 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Prestige Consumer Healthcare in the first quarter valued at $254,000. Sei Investments Co. lifted its stake in Prestige Consumer Healthcare by 3.2% in the first quarter. Sei Investments Co. now owns 215,271 shares of the company's stock valued at $17,051,000 after acquiring an additional 6,681 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Prestige Consumer Healthcare by 2.0% in the first quarter. Russell Investments Group Ltd. now owns 28,115 shares of the company's stock valued at $2,417,000 after acquiring an additional 561 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PBH. Wall Street Zen cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Finally, Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH traded up $1.3050 during mid-day trading on Friday, reaching $66.7550. 542,270 shares of the company were exchanged, compared to its average volume of 589,114. The company's 50-day simple moving average is $75.29 and its 200-day simple moving average is $81.18. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $3.29 billion, a P/E ratio of 15.67, a P/E/G ratio of 2.11 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a twelve month low of $62.95 and a twelve month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The company had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. During the same quarter in the prior year, the business posted $0.90 EPS. The business's quarterly revenue was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.